Dere Willard H 4

What Happened
Dere Willard, a director of Seres Therapeutics (MCRB), was granted a derivative award for 6,500 shares on July 8, 2026. The filing lists the acquisition as an award (derivative) with $0.00 reported as the amount paid. This is a grant of an option-like award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-08; Form 4 filed: 2026-07-10 (timely filing).
• Amount: 6,500 shares reported as a derivative award; reported cash paid: $0.00.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: the option vests and becomes exercisable on the earlier of (i) July 8, 2027, or (ii) the day immediately prior to the first annual meeting of stockholders occurring after July 8, 2026.
• No 10b5‑1 plan, tax-withholding, or late-filing indication shown in the provided data.

Context
This was an equity award (derivative grant) as part of compensation/retention rather than a market purchase or sale. The Form 4 shows $0 paid at grant and a vesting/exercisability schedule in the footnote; it does not indicate any immediate sale of shares. Such awards are common for directors and signal compensation arrangements rather than direct trading conviction.